Personalised risk-directed clot prevention for patients with cancer

癌症患者的个性化风险导向血栓预防

• 批准号: nhmrc : 1196211
• 金额: $ 64.52万
• 依托单位国家: 澳大利亚
• 项目类别: Investigator Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2025-12-31
• 项目状态: 未结题
• 来源: https://researchdata.edu.au/personalised-risk-directed-patients-cancer/1779099
• 关键词: Personalised; risk; directed; clot; prevention

Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.

血栓是癌症患者死亡的主要原因，仅次于癌症本身。该EL1计划包括临床和实验室研究，以评估个性化血栓预防对在门诊护理环境中接受癌症治疗的患者的影响。实验室研究和对“现实世界”中具有血栓形成高风险的癌症患者的结局进行评估，将提高对血栓和癌症的理解，以推进研究和临床实践。